ClinicalTrials.gg
RecruitingNCT07508124STRUMI-TUpdated Aug 7, 2026

Topical Steroids to Prevent Recurrent Urinary Tract Infections in Uncircumcised Male Infants: a Pilot Study

A Phase 4 interventional study of betamethasone valerate 0.1% cream and Placebo cream in Urinary Tract Infection, sponsored by Baylor College of Medicine. Recruiting at 3 sites in United States. Open to male participants aged 0 Months to 5 Months. Per ClinicalTrials.gov, last updated 2026-08-07.

Sponsored by Baylor College of Medicine · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Started May 2026; still recruiting 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
0 Months to 5 Months
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 275 studies in Urinary Tract Infections with a site in United States — 44 open to participants now, 57 under way, 2 of them phase 3. Urinary Tract Infections · United States.

Planned enrollment
153rd of 225
40 · median 100
Started
2026
with 18 others
Phase 4
40 of 275
10 open now
Primary completion
2027-12
later than 38 of 56 live
Registered
262nd of 275
by date
Lead sponsor
7 of 275
Baylor College of Medicine

Among the 275 studies in Urinary Tract Infections with a site in United States, this one is the 153rd largest by planned enrollment of the 225 interventional ones that give a count, is one of 19 that started in 2026, is one of 40 in phase 4, reaches primary completion later than 38 of the 56 other live ones, and was the 262nd registered.

Urinary Tract Infections

808 studies on the registry are indexed under Urinary Tract Infections; 135 are open to participants now.

Browse Urinary Tract Infections studies →

Open to participants now

44 of the 275 studies in Urinary Tract Infections with a site in United States are open now. Recruiting first, the newest first:

38 more — sign in →

All 44 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 84 Urinary Tract Infections studies recruiting now, 51 (61%) set no upper age limit and 23 (27%) stop at 75 or younger; 17 take children under 18; 15 take healthy volunteers.

This study: 0 Months to 5 Months · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 275 studies in Urinary Tract Infections with a site in United States, or all of them as a file.
02

Study summary

The goal of this smaller clinical trial is to evaluate the study design of this research to help prepare for a larger research study in the future. The future larger study would focus on whether steroid cream can reduce recurrent urinary tract infections in male infants, who are not circumcised.

Male infants, who are enrolled in this study, would receive either the steroid cream or a placebo cream (a look alike cream without steroids). The cream would be applied twice a week for four weeks. Then there would be two follow up visits with the research team to measure whether the infant experienced any urinary tract infections and to measure parent perceptions of their experience participating in the study.

Read the detailed description

This is a multi-center pilot study involving recruitment of uncircumcised male infants \< 6 months of age from outpatient clinics, emergency department and inpatient settings in Houston, Texas. Additionally, the pilot study will involve recruitment of hospitalized infants from Seattle Children's Hospital in Seattle, Washington.

Various strategies for screening and recruitment will be piloted across settings to identify the most effective processes for the future study. Hospitalized infants would be enrolled prior to discharge. Children recruited from the clinic or emergency department would be enrolled in the Texas Children's Hospital Clinical Research Center. Randomization would occur after enrollment and would be conducted by the investigational pharmacy. The research investigators will teach the legal guardians of the infants how to apply the cream.

The first follow up visit would occur after completion of the cream treatment and would be 28-38 days after being enrolled or after hospital discharge, whichever came later. The last follow up visit would occur 6-7 months after being enrolled or hospital discharge.

03

Conditions studied

  • Urinary Tract Infection

Keywords

  • urinary tract infection
  • uncircumcised male infants
  • betamethasone cream
  • steroid cream
04

Who can participate

Ages eligible
0 Months to 5 Months
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Uncircumcised male infants \< 6 months old
  2. Both physician and laboratory confirmed diagnosis of first UTI
  3. Fever (temperature ≥38.0 C) or hypothermia (temperature \<36.0 C) per ED/hospitalization or parental report

Exclusion criteria

Exclusion Criteria:

  1. Legal guardian not available to provide
  2. Infant in Child Protective Services (CPS) custody
  3. Legal guardian would like Urology referral for circumcision
  4. Circumcision is medically indicated due to recurrent episodes of balanitis or ballooning of foreskin during urination
  5. Past diagnosis of penile abnormalities (diagnoses of epispadius, hypospadias or congenital penile curvature (chordee))
  6. Prior use of topical therapy for phimosis
  7. History of to topical steroids
  8. Legal guardian is not fluent in English OR Spanish
  9. Foreskin assessed to be fully retractable
  10. Open wounds present on penis or in groin region
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
40 participants (estimated)

Study arms

  • Active comparator
    Participants randomized to receive steroid cream

    Drug: betamethasone valerate 0.1% cream

  • Placebo comparator
    Participants randomized to receive placebo cream.

    Drug: Placebo cream

Interventions

  • DrugBetamethasone ValerateStudies of Betamethasone ValerateBetamethasone Valerate pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Steroid cream applied to the foreskin and glans twice a day for four weeks.

  • DrugPlacebo cream

    Placebo cream is applied to the foreskin and glans twice a day for four weeks.

06

What researchers measure

Primary outcomes

  1. Feasibility of recruitment across different settings

    Defined as the consent rate of \>= 20% as stratified by setting (clinic/EC/inpatient)

    Time frame: up to 2 weeks

Secondary outcomes

  1. Rate of recurrent urinary tract infection

    Defined as at least one subsequent urinary tract infection as confirmed through parent report and medical record review.

    Time frame: Between 14 days of completing antibiotics for the first urinary tract infection and through the last follow up visit, which occurs 6 months after randomization.

  2. Total number of recurrent urinary tract infections

    Time frame: 6 month follow up period

  3. Number of subsequent hospitalizations for recurrent urinary tract infections

    Subsequent hospitalizations for recurrent urinary tract infections

    Time frame: 6 month follow up period

  4. Number of subsequent emergency department visits for recurrent urinary tract infection

    Subsequent emergency department visits, including urgent care, for recurrent UTI

    Time frame: Within 6 month follow up period

  5. Rate of provider diagnosed recurrent urinary tract infection

    Number of recurrent urinary tract infections that are diagnosed by the physician but do not necessarily meet laboratory criteria for urinary tract infection.

    Time frame: 6 month follow up period

  6. Number of Lumbar punctures

    Number of lumbar punctures received during a subsequent emergency department visit or hospitalization for recurrent urinary tract infection

    Time frame: 6 month follow up period

  7. Self reported Rate of Referral for Circumcision

    Parent reports referral to Urology for circumcision or circumcision performed within the 6 month follow up period.

    Time frame: During the 6 month follow up period

  8. Self Reported Adherence to Applying Topical Cream Regimen

    Adherence to applying the topical cream measured by asking the frequency of application in a questionnaire completed by the legal guardian.

    Time frame: Measured at 4 week follow up visit

  9. Rate of Adverse effects of cream

    Local or systemic side effects of the cream (e.g., irritation, local infection)

    Time frame: At 4 weeks

  10. Number of infants with Congenital anomalies of the kidney and urinary tract

    Number of participants with previously known or newly diagnosed genitourinary anomalies

    Time frame: From time of enrollment through last follow up visits 6 months later

  11. Number of subsequent clinic visits for recurrent urinary tract infection

    Subsequent clinic visits may include visits to the primary care physician or another physician in the clinic

    Time frame: During the 6 month follow up period

  12. Attrition rate

    Total number of missed visits at 4 weeks and 6 months. This will be measured by tracking of study visits.

    Time frame: Through the 6 month follow up period for each participant

  13. Parental acceptability of the study design

    Perceptions on any facilitators and barriers to participating in the study as related to enrollment, administration of the study cream and attending follow up visits. Qualitatively measured using semi-structured interviews.

    Time frame: At the 6 month follow up visit for each participant

07

Study locations

1 of 3 sites recruiting
  • Texas Children's Hospital Main campus
    Houston, Texas 77030, United States
    Recruiting
    • Sowdhamini Wallace, DO, MS · Contactswallace@bcm.edu · 832-824-5447
    • Sowdhamini Wallace, DO, MS · Principal investigator
    • Grace Truong, MD · Sub investigator
    • Chester Koh, MD, MBA · Sub investigator
    • Jaqueline Broda, MPAS, PA-C · Sub investigator
    • Saamia Masoom, MD · Sub investigator
  • Texas Children's Hospital West Campus
    Katy, Texas 77094, United States
    Not yet recruiting
    • Sowdhamini Wallace, DO, MS · Contactswallace@bcm.edu · 832-824-5447
    • Sowdhamini Wallace, DO, MS · Principal investigator
    • Marina Bishai, DO · Sub investigator
  • Seattle Children's Hospital
    Seattle, Washington 98105, United States
    Not yet recruiting
08

References and documents

Publications

  • Lee JW, Cho SJ, Park EA, Lee SJ. Topical hydrocortisone and physiotherapy for nonretractile physiologic phimosis in infants. Pediatr Nephrol. 2006 Aug;21(8):1127-30. doi: 10.1007/s00467-006-0104-8. Epub 2006 Jun 22. PubMed 16791612 ↗
  • Chen CJ, Satyanarayan A, Schlomer BJ. The use of steroid cream for physiologic phimosis in male infants with a history of UTI and normal renal ultrasound is associated with decreased risk of recurrent UTI. J Pediatr Urol. 2019 Oct;15(5):472.e1-472.e6. doi: 10.1016/j.jpurol.2019.06.018. Epub 2019 Jun 25. PubMed 31345734 ↗
  • Moreno G, Ramirez C, Corbalan J, Penaloza B, Morel Marambio M, Pantoja T. Topical corticosteroids for treating phimosis in boys. Cochrane Database Syst Rev. 2024 Jan 25;1(1):CD008973. doi: 10.1002/14651858.CD008973.pub3. PubMed 38269441 ↗
  • Dave S, Afshar K, Braga LH, Anderson P. Canadian Urological Association guideline on the care of the normal foreskin and neonatal circumcision in Canadian infants (full version). Can Urol Assoc J. 2018 Feb;12(2):E76-E99. doi: 10.5489/cuaj.5033. Epub 2017 Dec 1. No abstract available. PubMed 29381458 ↗
  • Conway PH, Cnaan A, Zaoutis T, Henry BV, Grundmeier RW, Keren R. Recurrent urinary tract infections in children: risk factors and association with prophylactic antimicrobials. JAMA. 2007 Jul 11;298(2):179-86. doi: 10.1001/jama.298.2.179. PubMed 17622599 ↗
  • Khan A, Jhaveri R, Seed PC, Arshad M. Update on Associated Risk Factors, Diagnosis, and Management of Recurrent Urinary Tract Infections in Children. J Pediatric Infect Dis Soc. 2019 May 11;8(2):152-159. doi: 10.1093/jpids/piy065. PubMed 30053044 ↗
  • Shaikh N, Morone NE, Bost JE, Farrell MH. Prevalence of urinary tract infection in childhood: a meta-analysis. Pediatr Infect Dis J. 2008 Apr;27(4):302-8. doi: 10.1097/INF.0b013e31815e4122. PubMed 18316994 ↗

Individual participant data

Plan to share: Yes — After publication of this study, a releasable database will be produced and completely de-identified in accordance with the definitions provided in the Health insurance Portability and Accountability Act (HIPAA). Namely, all identifiers specified in HIPAA will be recoded in a manner that will make it impossible to deduce or impute the specific identity of any patient. The database will not contain any institutional identifiers. The PI will prepare a data dictionary that provides a concise definition of every data element included in the database. The releasable database will be provided to users in electronic form.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form

Time frame: The de-identified database and data dictionary will be available after publication of this study and up to five years after the publication date.

Access criteria: The database and data dictionary would be made available to researchers and clinicians after publication of this study. The data will be made available upon publication to researchers who provide a methodologically sound proposal for use in achieving the goals of the approved proposal. Proposals should be submitted to Sowdhamini Wallace (swallace@bcm.edu).

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2026 (actual). Primary completion is estimated for Dec 2027, 19 months after the start.

Of 45 non-industry phase 4 interventional studies under Urinary Tract Infections, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 54. This study's planned 19 months is below that.

Counting every sponsor, half of 51 studies reached it within 37 months; a quarter within 22 and three quarters within 50.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 21, 2026
First posted
Apr 2, 2026
StartActual
May 8, 2026
Primary completionEst.
Dec 2027
CompletionEst.
Dec 2027
Last update
Aug 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 7, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07508124
Responsible party
Sowdhamini Wallace (Associate Professor of Pediatrics, Baylor College of Medicine) — Principal investigator
First posted
Apr 2, 2026
Start date
May 8, 2026
Primary completion
Dec 2027 (estimated)
Completion
Dec 2027 (estimated)
Last update
Aug 7, 2026

Study contacts

Sowdhamini Wallace, DO, MS
Contact
swallace@bcm.edu
18328245447

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Betamethasone Valerate

Start the discussion